Skip to main content

Table 1 Criteria for ruxolitinib failure in patients with MF—adapted from [52, 65]

From: Novel therapeutics in myeloproliferative neoplasms

Criteria

Ruxolitinib duration

Cytopenias

Spleen size

Relapsed

 ≥ 3 months

–

Regrowth < 10% SVR or < 30% decrease in spleen size by palpation from baseline following an initial response

Refractory

 ≥ 3 months

–

 < 10% SVR or < 30% decrease in spleen size by palpation from baseline

Intolerant

 ≥ 28 days

New grade ≥ 3 thrombocytopenia, anemia, hematoma/hemorrhage or RBC transfusion requirement ≥ 2 units/month for 2 months

–

  1. SVR spleen volume reduction, RBC red blood cell